The present invention relates to pharmaceutical agents which are agents
for the prophylaxis or treatment of hypogonadism, male climacteric
disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents
frailty suppressants, muscle strength enhancers, muscle increasing
agents, cachexia suppressants, body weight decrease suppressants, agents
for the prophylaxis or treatment of prostate hypertrophy, amyotrophy or
muscle loss caused by a disease or an agent for reducing the prostate
weight.
The present invention also relates to methods for the prophylaxis or
treatment of hypogonadism, male climacteric disorder, frailty, cachexia
or osteoporosis in a mammal, which comprises administering an effective
amount of the pharmaceutical agents of the present invention or a prodrug
thereof; use of the pharmaceutical agents of the present invention or a
prodrug thereof for the production of an agent for the prophylaxis or
treatment of hypogonadism, male climacteric disorder, frailty, cachexia
or osteoporosis; and the like.